



The modulatory effect of pomegranate mesocarp on ribose-glycated protein


Piteesha Ramlagan¹, Vidushi Neergheen-Bhujun¹, Emmanuel Bourdon², Theeshan Bahorun³

¹ Department of Health Sciences, Faculty of Science and ANDI Center for Biomedical and Biomaterials Research University of Mauritius


² Université de La Réunion, INSERM, UMR 1188 Diabète athérothrombose Thérapies Réunion Océan Indien (DéTROI), plateforme CYROI, Saint-Denis de La Réunion, France

³ ANDI Center for Biomedical and Biomaterials Research, University of Mauritius

Introduction: Ribose




Introduction: Diabetes Statistics




Introduction: Diabetes Statistics

Diabetes estimates (20-79 years)	Mauritius	Reunion	Madagascar	Comoros
Prevalence, %	22	13.8	3.9	11.9
% of diabetic population	17.9	12.9	1.45	3.83
Diabetes related deaths	2609.3	NA	4685.6	339.7
Mean diabetes related expenditure (USD), per person	535	NA	27	100

Introduction: glycation




Introduction: AGEs & diabetic complications



Over-expressed by AGEs

Insulin resistance


Pro-atherogenic




Introduction: pomegranate

- Functional food with anti-diabetic potential




- Non-edible parts bioactive




Our focus



Anti-diabetic potencies of PME




Anti-glycative activity of PME





Anti-glycative activity of PME

Experimental group	Level of				<i>AOPP (nmol chloramine-T/mg protein)</i>
	<i>Fluorescent AGEs (% BSA)</i>	<i>Fructosamine (mMDMF)</i>	<i>Protein carbonyl (%)</i>	<i>BSA)</i>	
BSA	100	0.711 ± 0.10	100		0.07 ± 0.01
BSA + GLU+					
DMSO	176.21 ± 2.32 ***	4.97 ± 0.28 ***	107.29 ± 5.13		0.33 ± 0.05
PME	102.15 ± 0.49 ###	2.99 ± 0.29 ***	100.26 ± 11.62		0.35 ± 0.08
Aminoguanidine	103.46 ± 0.60 ###	3.49 ± 0.26 ***	94.61 ± 5.21		0.36 ± 0.03
BSA + RIB +					
DMSO	1346.69 ± 20.82 ***	4.86 ± 0.15 ***	175.01 ± 6.14 ***		3.91 ± 0.18 ***
PME	103.36 ± 12.36 ###	3.14 ± 0.35 ***	99.82 ± 9.23 ###		1.48 ± 0.27 ***
Aminoguanidine	114.85 ± 18.10 ###	3.12 ± 0.25 ***	131.85 ± 5.94 *		2.55 ± 0.14 ***


Effect of PME in *in vitro* diabetic model







PME protects against AGEs-induced cell death



PME counteracts AGEs-induced oxidative stress and inflammation



PME lowers accumulation of oxidatively modified proteins



Fractionation of PME



Pomegranate extract
(PME)

Dissolved in water and partitioned in dichloromethane

DCM
fraction

Aqueous
phase

Partitioned in ethyl acetate

EtAc
fraction

Aqueous
phase

Partitioned in *n*-butanol

BUT
fraction

Water
residue


Polyphenolic content of pomegranate mesocarp fractions

Fraction	Total phenolic content	Total flavonoid content	Hydrolysable tannin content
Crude	483.97 ± 18.32^b	383.78 ± 9.20^c	704.52 ± 7.74^d
Dichloro-methane	80.48 ± 2.85^e	18.04 ± 0.34^e	127.61 ± 7.09^e
Ethyl acetate	570.14 ± 14.13^a	533.85 ± 12.02^b	901.46 ± 11.64^b
n-butanol	323.27 ± 6.40^d	681.75 ± 5.97^a	945.69 ± 12.86^a
Water residue	431.78 ± 8.01^c	350.25 ± 14.71^d	739.08 ± 3.89^c

Antioxidant activity of pomegranate mesocarp fractions


Fraction	IC ₅₀ value (μg/mL) for	
	ABTS radical scavenging	DPPH radical scavenging
Crude	2.340 ± 0.017 ^a	3.396 ± 0.341 ^a
Dichloro-methane	39.732 ± 1.752 ^b	88.353 ± 8.904 ^b
Ethyl acetate	1.638 ± 0.081 ^a	2.962 ± 0.190 ^a
n-butanol	1.181 ± 0.042 ^a	2.035 ± 0.335 ^a
Water residue	2.574 ± 0.177 ^a	3.575 ± 0.462 ^a

Pomegranate mesocarp fractions modulate CD36 expression



Effect of PME on CD36 protein expression


(Densitometry values are expressed relative to control and normalized against β-actin)




Effect of crude and fractions of mesocarp on CD36 protein expression from preadipocytes

Densitometry values are expressed relative to control and normalized against β-actin.

Conclusion



Acknowledgement



Thank you

Merci

Misaotra anao

Marahaba